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Introduction DMD #41087 5 form of di-/tripeptides, originating from the diet and gastrointestinal secretions. However, intestinal PEPT1 also acts as a vehicle for the effective absorption of peptide-like drugs with different conformations, sizes, polarities and charges (e.g., β -lactam antibiotics, angiotensinconverting enzyme inhibitors, renin inhibitors, bestatin and the antiviral prodrug valacyclovir).
Because of its ability to absorb a large and varied number of the therapeutic agents, PEPT1 is viewed as an appealing target in drug development.
PEPT1 may influence drug disposition because of its localization in tissues that can affect the distribution and/or elimination pathways of peptides/mimetics. For example, PEPT1 is expressed at the apical membrane of S1 segments in kidney proximal convoluted tubule (Shen et al., 1999) , thereby, having a role in renal reabsorption. PEPT1 is also expressed in pancreas, bile duct, liver, adrenal gland, testes, ovary, and uterus (Fei et al., 1994; Liang et al., 1995; Knutter et al., 2002; Lu and Klaassen, 2006) and, as result, may have a role in disposition of small peptide/mimetics in those tissues. PEPT1 is not confined to plasma membranes since immunofluorescense microscopy and transport studies have shown this protein to be expressed in lysosomal membranes of liver (Thamotharan et al., 1997) , renal (Zhou et al., 2000) and pancreatic cells (Bockman et al., 1997) .
Studies in relevant in vivo models of PEPT1 are sparse and confounded, primarily because DMD #41087
Materials and Methods
Animals. Wild-type and Pept1 knockout mice (8-10 weeks old and gender-matched) were used in these experiments (Hu et al., 2008) . Mice were housed under temperature-controlled conditions with 12-hr light and dark cycles, and were provided a standard diet along with water ad libitum (Unit for Laboratory Animal Medicine, University of Michigan, Ann Arbor, MI).
Animal studies were carried out in accordance with the Guide for the Care and Use of Laboratory Animals as adopted and promulgated by the U.S. National Institutes of Health.
Materials.
[ 
Systemic Exposure and Tissue Distribution Studies after Oral GlySar. Wild-type and
Pept1 knockout mice were fasted overnight prior to each experiment. GlySar was dissolved in normal saline and administered at escalating doses of 1, 10, 100, 1000, and 5000 nmol/g body weight.
[ 3 H]GlySar (0.5 μ Ci/g body weight) was added to the aqueous solution and given orally, by gavage (20G needle) at a volume of 10 μ L/g body weight for all doses. Serial blood samples (20 μ L) were collected by tail nicks at 0. 5, 5, 10, 20, 30, 45, 60, 75, 90, 120, 180, 240, 360 and 480 min. Blood samples were transferred to 0.2 mL thin-walled PCR tubes containing 7.5% potassium EDTA and centrifuged at 3300 g for 3 min, ambient temperature. A 5-10 μ L aliquot of plasma was then transferred to a scintillation vial and 6 mL CytoScint scintillation fluid (MP Biomedicals, Solon, OH) was added to the sample. Radioactivity of the plasma sample was This article has not been copyedited and formatted. The final version may differ from this version. Coulter Inc., Fullerton, CA). It should be noted that mice were returned to their cages between blood sampling where they had free access to water. Food was provided in their cages four hours after the oral gavage. One and four hours after oral dosing, mice were given intraperitoneal injections of 0.25 mL warm saline in order to prevent dehydration. The cage was equipped with a heating pad to help the mice maintain normal body temperature.
After the last blood sample was obtained (8 hr), several organs/tissues (e.g., kidney, liver, lung, pancreas, spleen, small and large intestines, bile duct, ovary, testis, prostate, skeletal muscle, heart, eye, and cerebral cortex) were collected. One kidney was collected intact and the other kidney was separated into renal cortex, outer medulla, and inner medulla. The small intestine was cut into duodenum, proximal jejunum, mid-small intestine, distal ileum, proximal colon, and distal colon; each segment was washed with pre-warmed saline solution to remove fecal material and then blotted dry prior to weighing. Tissue samples were solubilized in 0.5 mL of 1 M hyamine hydroxide for 24 hr, 37ºC. A 40 μ L aliquot of hydrogen peroxide (30%) was then added to each sample and incubated for another 24 hr, 37ºC. A 6 mL aliquot of CytoScint scintillation fluid was added to the tissue sample, and radioactivity was measured on a dualchannel liquid scintillation counter.
At 5 min prior to harvesting the tissues, [ 14 C]dextran MW 70,000 (0.15 μ Ci/mouse) was administered via tail vein injection to determine the tissue vascular space. As described previously (Ocheltree et al., 2005; Shen et al., 2007) , the corrected tissue concentrations of GlySar (C tiss.corr ; nmol/g wet tissue) were calculated as:
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Results
Absorption Profile and Systemic Exposure of GlySar after Escalating Oral Doses. As shown in Fig. 1 (A-C) , wild-type and Pept1 knockout mice had very different absorption profiles of GlySar, as analyzed over 120, 240, and 480 min, respectively, following the 10 nmol/g dose.
In wild-type mice, GlySar plasma concentrations rose rapidly and reached a single plateau level at approximately 90 min. In contrast, GlySar plasma levels in Pept1 knockout mice reached an initial plateau at about 90 min and then rose to a second plateau at about 240 min. Moreover, the oral absorption of GlySar was substantially reduced in Pept1 knockout compared to wild-type mice (p < 0.01), as judged by the extent of systemic exposure (AUC), especially during the first 2 hr. Similar absorption profiles and AUC differences were observed at the 1, 100, 1000, and 5000 nmol/g doses (data not shown). In fact, when all five doses were considered, the systemic exposure of GlySar in Pept1 knockout mice was about 40, 55, and 70% of that achieved in wildtype animals over the 120, 240, and 480 min time periods, respectively (Table 1) .
To further illustrate differences in the absorption rate of GlySar between genotypes, partial AUC vs. time profiles after the 10 nmol/g dose are shown in Fig. 2 (A-C). As observed in wildtype mice, the curve had a single slope from 20 to 480 min. However, for Pept1 knockout mice, the curve had two distinct slopes from 20 to 480 min; a slower slope from 20-120 min and a faster slope from 240-480 min which was parallel to that of wild-type mice. The transition point for the two slopes in Pept1 knockout mice was approximately 180 min based on our observation of the data and the confines of experimental design. As shown in Table 2 , the initial slope (20-120 min) was 60% lower in Pept1 knockout mice compared to wild-type animals for all five
This article has not been copyedited and formatted. The final version may differ from this version. dose levels. In contrast, the latter slope (240-480 min) was very similar between the two genotypes (~ 10% difference).
To probe whether or not the PEPT1-mediated absorption of GlySar was capacity-limited, the in vivo systemic exposure of dipeptide was evaluated after escalating oral doses of 1-5000 nmol/g in both genotypes. As demonstrated in Fig. 3 (A-C), the extent of absorption appears linear for wild-type and Pept1 knockout mice over the 1-100 nmol/g dose range since no significant changes were observed in the dose-corrected AUC values of GlySar. Although statistically significant differences were observed at the two highest dose levels, these changes were small (i.e., < 20 and 35% reduction, respectively, at 1000 and 5000 nmol/g), and in the same direction for both genotypes.
Systemic Exposure of GlySar after an Intravenous Bolus Dose. Fig. 4 depicts the plasma concentration-time profiles of GlySar in wild-type and Pept1 knockout mice after a 10 nmol/g intravenous bolus dose. As observed in both genotypes, there is a rapid initial decline in plasma concentrations over the first 1 hr followed by a protracted terminal disposition phase over the next 7 hr. As a result, it was not possible to obtain an accurate assessment of the terminal half-life of GlySar and its extrapolated area for AUC (0-inf) determinations. Still, as evaluated over 8 hr, there was a small but significant 24% difference in AUC (0-480 min) between wild-type and Pept1 knockout mice (p < 0.05).
Tissue Distribution of GlySar after Oral and Intravenous Dosing.
To capture the tissue distribution of GlySar during its initial absorptive phase, experiments were performed 1 hr after dosing the dipeptide orally at 10 nmol/g. As shown in Fig. 5A , PEPT1 ablation had a major impact on the accumulation of GlySar in almost all tissues studied. In particular, GlySar accumulation was about 7-fold lower in the duodenum of Pept1 knockout mice as compared to wild-type animals. The accumulation of GlySar in all other tissues was 2-to 4-fold lower in mice lacking PEPT1. Since systemic plasma concentrations were the driving force for GlySar distribution in all tissues except the intestines, and were dramatically different between the two genotypes 1 hr after oral dosing (Fig. 1) , the data were also expressed as tissue-to-plasma ratios (except for intestines) to rule out any differences being due to systemic exposure alone. As shown in Fig. 5B , no statistical differences were observed in the tissue-to-plasma concentration ratios of GlySar in wild-type and Pept1 knockout mice in these non-intestinal tissues.
To capture the tissue distribution of GlySar during its late absorptive and disposition phases, experiments were performed 8 hr after dosing the dipeptide orally and intravenously at 10 nmol/g. When administered orally, GlySar accumulation was almost 10-fold lower in the duodenum (p < 0.001) and 1.5-fold lower in the distal ileum (p < 0.05) of Pept1 knockout mice compared to wild-type animals (Fig. 6A) ; no statistical differences were observed in any other tissues between the two genotypes. Likewise, no differences were observed between wild-type and Pept1 knockout mice when the tissue concentrations of GlySar (intestines omitted) were normalized by their corresponding plasma concentrations (Fig. 6B) . When administered intravenously, GlySar accumulation was 1.5-to 9.5-fold lower in several tissues (i.e., testis, pancreas, heart, small and large intestines, skeletal muscle, eye, and cerebral cortex) of Pept1 knockout mice as compared to wild-type animals (Fig. 7A) . However, when the tissues were normalized for differences in plasma concentration (including the intestines), these statistical differences disappeared, except for that in mid-small intestine (p < 0.05; Fig. 7B ).
Discussion
In this study, we report several new findings regarding the in vivo oral absorption and disposition of GlySar in wild-type and Pept1 knockout mice. In particular, we found the following: 1) PEPT1 ablation caused significant reductions in the systemic exposure of GlySar following oral doses of 1-5000 nmol/g; 2) the oral absorption profile of GlySar was very different between the two genotypes and absorption rate was slower in Pept1 knockout mice; 3) the oral absorption GlySar was linear over 1-100 nmol/g doses, but was reduced to a minor extent (< 20 and 35%, respectively) at 1000 and 5000 nmol/g doses; this change was observed in both genotypes; and 4) with the exception of intestines, changes in tissue distribution were unremarkable between wild-type and Pept1 knockout mice, largely reflecting differences in systemic exposure of the dipeptide. This study demonstrates that, under in vivo conditions, PEPT1 maintains a very high capacity for absorbing GlySar and potentially other peptide/mimetic substrates.
GlySar was studied over a 1-5000 nmol/g dose range because it reflects the physiological range of daily protein consumption. According to Ganapathy et al. (2006) Notwithstanding this uncertainty, erratic absorption profiles have also been explained by the presence of enterohepatic circulation (Roberts et al., 2002) , fractionated gastric emptying (Oberle and Amidon, 1987) , absorption windows along the intestinal tract (Gramatte et al., 1994) , and a presystemic storage compartment (Weitschies et al., 2005) . Using a previously described HPLC method with radiochemical detection (Ocheltree et al., 2005) , GlySar instability was discounted as a possible confounding factor because, after oral dosing, no differences were observed between the two genotypes after both 8 hr (≥ 80% unchanged) and 24 hr urinary collections (77% unchanged).
As noted before, the dose-corrected AUC values of GlySar were 20% lower at the 1000 vs.
1 nmol/g oral dose and 35% lower at the 5000 vs. 1 nmol/g oral dose (Fig. 3) . Although this finding suggests that intestinal PEPT1 may become saturated at the two higher doses, precipitation of GlySar in the gastrointestinal tract is also possible. In fact, a 10,000 nmol/g oral dose was omitted from our initial study design because of GlySar precipitating out of the aqueous solution. Masaoka et al. (2006) reported that, for poorly soluble compounds, concentrations in the small intestine could be 2-to 5-fold greater than anticipated because of rapid water absorption in the jejunum. Moreover, it is very unlikely that PEPT1 saturation alone was responsible for the reduction in dose-corrected AUC values since similar results were found in Pept1 knockout mice. Taken as a whole, it is difficult to distinguish which mechanism is operative in wild-type mice and may, in fact, reflect both saturation of intestinal PEPT1 and precipitation of GlySar. In Pept1 knockout mice, reduced AUC values relative to oral dose are probably due to precipitation of dipeptide in the small intestine.
During previous in situ single-pass perfusions, the jejunal permeability of GlySar was reduced by > 90% in Pept1 knockout compared to wild-type mice (Jappar et al., 2010) .
Although the present in vivo study corroborates the relevance of intestinal PEPT1 in oral dipeptide absorption, the magnitude of change was smaller than expected. Given that GlySar is transported by PEPT1, and that PEPT1 is abundantly expressed in all regions of mouse small This article has not been copyedited and formatted. The final version may differ from this version. absorption of cephalexin. These authors also noted that, during simulation studies, an 83% bioavailability would be expected for cephalexin in the absence of PEPT1 function due to a compensatory passive diffusion. It should be appreciated that other POT family members (i.e., PEPT2, PHT1 and PHT2) were not upregulated during PEPT1 ablation (Hu et al., 2008) and, therefore, cannot explain the greater than expected absorption/systemic exposure of GlySar in Pept1 knockout mice.
Studies comparing the pharmacokinetics of GlySar in wild-type and Pept2 null mice have indicated that, of the 46% of dipeptide reabsorbed in the kidney of wild-type mice, PEPT2 and PEPT1 accounted for 86 and 14%, respectively, of this process (Ocheltree et al., 2005) . Since
GlySar is metabolically stable, one would expect the AUC of dipeptide to be 14% lower in Pept1
This article has not been copyedited and formatted. The final version may differ from this version. knockout than wild-type mice when administered intravenously to both genotypes. While the plasma concentration-time profiles of GlySar were almost superimposable between wild-type and Pept1 null animals in the one study (Hu et al., 2008) , the systemic exposure of intravenously administered GlySar in the present study was 24% lower in Pept1 knockout mice than wild-type animals. Given that both studies were not designed in a cross-over fashion, and there is variability between animals and experimental time periods, a 12% difference (on average) is reasonably close to the 14% difference that would be predicted from other experiments. Just as tissue distribution differences of GlySar, during PEPT2 ablation, are most noticeable in the kidney and choroid plexus (i.e., tissues which abundantly express this protein) (Ocheltree et al., 2005) , the most noticeable differences in GlySar tissue distribution, during PEPT1 ablation (i.e., this study), are consistently found in the small intestine. However, once outside the enteric system, PEPT1 has little if any influence on the tissue distribution of GlySar, especially when normalized for differences in dipeptide plasma concentration. Alternatively, one cannot exclude the possibility that biological variation may preclude minor differences from being observed in PEPT1-mediated effects on GlySar tissue distribution.
Mouse models of PEPT1 appear to be reasonable surrogates of its human ortholog for several reasons. First, the transport properties of peptides/mimetics are similar with respect to driving forces, substrate specificity, and substrate affinity in cell culture systems expressing human and mouse PEPT1 (Liang et al., 1995; Mackenzie et al., 1996; Fei et al., 2000) . Second, PEPT1 is found in the appropriate location of renal and intestinal tissues, with comparable expression levels in both species (Liang et al., 1995; Zhang et al., 2004; Hu et al., 2008 (Walker et al., 1998; Groneberg et al., 2001 ). Third, gene expression studies
show that mouse and human have intestinal expression levels of PEPT1 that are similar, whereas PEPT1 protein in rat is several-fold greater (Kim et al., 2007) . And finally, mouse and human orthologs have high similarity in their genomic organization (Urtti et al., 2001 ).
In conclusion, our study is unique in providing the first comprehensive analysis of the absorption profile of a dipeptide, after escalating oral doses. In particular, we demonstrated that the absorption rate of GlySar was dramatically altered by PEPT1 ablation. Although GlySar's extent of absorption was significantly reduced in Pept1 knockout mice, it was less than predicted, probably reflecting the continuous passive diffusion of GlySar as it traveled down the entire length of small intestine. Other than small intestine, the effect of PEPT1 on GlySar tissue distribution was unremarkable. Future studies will be directed at studying the in vivo absorption and disposition of peptide-like drugs (e.g., cefadroxil and valacyclovir) and, in particular, to test whether or not intestinal PEPT1 is saturable at therapeutic doses of drug.
